Literature DB >> 28205111

Risk Factors for Bile Duct Injury After Percutaneous Thermal Ablation of Malignant Liver Tumors: A Retrospective Case-Control Study.

Man-Xia Lin1, Jie-Yi Ye1, Wen-Shuo Tian1, Ming Xu1, Bo-Wen Zhuang1, Ming-De Lu1,2, Xiao-Yan Xie3, Ming Kuang1,2.   

Abstract

BACKGROUND: Bile duct injury after ablation of malignant liver tumors (MLTs) was not unusual and should be avoided. However, few studies have focused on evaluating the risk factors for intrahepatic bile duct injury. AIM: To evaluate the risk factors for intrahepatic bile duct injury after ablation of MLTs and to evaluate the minimum safe distance for ablating tumors abutting bile ducts.
METHODS: Sixty-five patients with intrahepatic bile duct injury after ablation of MLTs, and 65 controls were recruited. Risk factors for intrahepatic bile duct injury were analyzed. Tumor location was recorded as ≤5 mm (group A), 5-10 mm (group B), and >10 mm (group C) from the right/left main duct or segmental bile duct.
RESULTS: Ascites history (P < 0.001), TACE treatment history (P = 0.025), intrahepatic bile duct dilatation before ablation (P < 0.001), and tumor location (P = 0.000) were identified as significant risk factors for intrahepatic bile duct injury. Significant differences in the risk of intrahepatic bile duct injury were found between groups B and C (P = 0.000), but not between groups A and B (P = 0.751). Ascites history (P = 0.002) and tumor location (P < 0.001) were independent predictors with the OR (95 % confidence interval) of 39.31(3.95-391.69) and 16.56 (5.87-46.71), respectively.
CONCLUSIONS: Bile duct injury after ablation of MLTs was the result of local treatment-related factors combined with the patients' general condition. The minimum safe distance for ablation of tumor abutting a bile duct was 10 mm.

Entities:  

Keywords:  Bile duct injury; Malignant liver tumors; Percutaneous; Risk factors; Thermal ablation

Mesh:

Year:  2017        PMID: 28205111     DOI: 10.1007/s10620-016-4312-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

Review 1.  Complications after percutaneous ablation of liver tumors: a systematic review.

Authors:  Eylon Lahat; Rony Eshkenazy; Alex Zendel; Barak Bar Zakai; Mayan Maor; Yael Dreznik; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Society of Interventional Radiology clinical practice guidelines.

Authors:  David Sacks; Tricia E McClenny; John F Cardella; Curtis A Lewis
Journal:  J Vasc Interv Radiol       Date:  2003-09       Impact factor: 3.464

Review 3.  Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough.

Authors:  G D Dodd; M C Soulen; R A Kane; T Livraghi; W R Lees; Y Yamashita; A R Gillams; O I Karahan; H Rhim
Journal:  Radiographics       Date:  2000 Jan-Feb       Impact factor: 5.333

Review 4.  Complications of radiofrequency coagulation of liver tumours.

Authors:  S Mulier; P Mulier; Y Ni; Y Miao; B Dupas; G Marchal; I De Wever; L Michel
Journal:  Br J Surg       Date:  2002-10       Impact factor: 6.939

5.  [Clinical evaluation of the risk factors for liver abscess after TACE or RFA].

Authors:  Satoshi Oshima; Naoko Tani; Kenji Takaishi; Miki Hirano; Yoichi Makari; Minako Hoshi; Takashi Doi; Hiroshi Matsuno; Yuko Kobori; Teruyuki Kobayashi; Satoshi Hyuga; Kimimasa Ikeda; Eiji Kurokawa; Shinji Tamura; Yutaka Inoue; Kazuhiro Nakajima
Journal:  Gan To Kagaku Ryoho       Date:  2014-11

6.  Biloma formation after radiofrequency ablation of hepatocellular carcinoma: incidence, imaging features, and clinical significance.

Authors:  Il Soo Chang; Hyunchul Rhim; Seong Hyun Kim; Young-sun Kim; Dongil Choi; Yulri Park; Hyo Keun Lim
Journal:  AJR Am J Roentgenol       Date:  2010-11       Impact factor: 3.959

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Major complications after radio-frequency thermal ablation of hepatic tumors: spectrum of imaging findings.

Authors:  Hyunchul Rhim; Kwon-Ha Yoon; Jeong Min Lee; Yoonkoo Cho; June-Sik Cho; Seung Hoon Kim; Won-Jae Lee; Hyo Keun Lim; Gyoung-Jin Nam; Sang-Suk Han; Yun Hwan Kim; Cheol Min Park; Pyo Nyun Kim; Jae-Young Byun
Journal:  Radiographics       Date:  2003 Jan-Feb       Impact factor: 5.333

9.  Ultrasonography-guided percutaneous radiofrequency ablation of hepatocellular carcinomas: a feasibility scoring system for planning sonography.

Authors:  Hyunchul Rhim; Dongil Choi; Young-sun Kim; Hyo K Lim; Bong-Keun Choe
Journal:  Eur J Radiol       Date:  2009-05-07       Impact factor: 3.528

10.  Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization.

Authors:  Ichiro Sakamoto; Soji Iwanaga; Kenji Nagaoki; Yojiro Matsuoka; Kazuto Ashizawa; Masataka Uetani; Toshio Fukuda; Tomoaki Okimoto; Sadayuki Okudaira; Katsuhisa Omagari; Kuniaki Hayashi; Naofumi Matsunaga
Journal:  AJR Am J Roentgenol       Date:  2003-07       Impact factor: 3.959

View more
  3 in total

1.  Prevention of major biliary complications by fusion imaging for thermal ablation of malignant liver tumors adjacent to the bile ducts: a preliminary comparative study.

Authors:  Jia Liu; Lu Li; Qingjing Zeng; Rongqin Zheng; Kai Li
Journal:  Abdom Radiol (NY)       Date:  2022-09-19

2.  Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study.

Authors:  Yujia You; Yinglin Long; Ronghua Yan; Liping Luo; Man Zhang; Lu Li; Qingjing Zeng; Kai Li; Rongqin Zheng; Erjiao Xu
Journal:  Front Oncol       Date:  2021-03-01       Impact factor: 6.244

3.  The Learning Curve for Thermal Ablation of Liver Cancers: 4,363-Session Experience for a Single Central in 18 Years.

Authors:  Xiang Jing; Yan Zhou; Jianmin Ding; Yijun Wang; Zhengyi Qin; Yandong Wang; Hongyu Zhou
Journal:  Front Oncol       Date:  2020-10-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.